Epstein-Barr_JJ
virus_NN
nuclear_JJ
antigen_NN
2_CD
-LRB-_-LRB-
EBNA2_NN
-RRB-_-RRB-
-_:
estrogen_NN
receptor_NN
fusion_NN
proteins_NNS
complement_VBP
the_DT
EBNA2-deficient_JJ
Epstein-Barr_JJ
virus_NN
strain_NN
P3HR1_NN
in_IN
transformation_NN
of_IN
primary_JJ
B_NN
cells_NNS
but_CC
suppress_VBP
growth_NN
of_IN
human_JJ
B_NN
cell_NN
lymphoma_NN
lines_NNS
._.

To_TO
develop_VB
a_DT
transformation_NN
system_NN
with_IN
a_DT
conditional_JJ
Epstein-Barr_JJ
virus_NN
nuclear_JJ
antigen_NN
2_CD
-LRB-_-LRB-
EBNA2_NN
-RRB-_-RRB-
gene_NN
,_,
we_PRP
fused_VBD
the_DT
hormone_NN
binding_NN
domain_NN
of_IN
the_DT
estrogen_NN
receptor_NN
to_TO
the_DT
N_NN
or_CC
C_NN
terminus_NN
of_IN
EBNA2_NN
._.

In_IN
promoter_NN
transactivation_NN
as_RB
well_RB
as_IN
primary_JJ
B_NN
cell_NN
transformation_NN
assays_NNS
these_DT
chimeric_JJ
EBNA2_NN
proteins_NNS
are_VBP
able_JJ
to_TO
substitute_VB
for_IN
wild-type_JJ
EBNA2_NN
in_IN
the_DT
presence_NN
of_IN
estrogen_NN
._.

Here_RB
we_PRP
provide_VBP
evidence_NN
that_IN
this_DT
transformation_NN
is_VBZ
the_DT
result_NN
of_IN
double_JJ
infection_NN
of_IN
a_DT
cell_NN
with_IN
two_CD
virions_NNS
,_,
the_DT
P3HR1_NN
virus_NN
genome_NN
and_CC
a_DT
mini-EBV_NN
plasmid_NN
carrying_VBG
the_DT
chimeric_JJ
EBNA2_NN
gene_NN
._.

Unexpectedly_RB
,_,
expression_NN
of_IN
the_DT
same_JJ
EBNA2-oestrogen_JJ
receptor_NN
fusion_NN
protein_NN
in_IN
established_JJ
human_JJ
B_NN
cell_NN
lymphoma_NN
lines_NNS
resulted_VBD
in_IN
growth_NN
retardation_NN
or_CC
growth_NN
arrest_NN
upon_IN
the_DT
addition_NN
of_IN
estrogen_NN
._.

By_IN
titrating_VBG
the_DT
estrogen_NN
concentration_NN
in_IN
these_DT
stably_RB
transfected_VBN
cells_NNS
,_,
the_DT
growth_NN
retarding_NN
and_CC
the_DT
transactivating_VBG
function_NN
of_IN
the_DT
chimeric_JJ
proteins_NNS
could_MD
not_RB
be_VB
dissociated_VBN
._.

We_PRP
propose_VBP
that_IN
growth_NN
inhibition_NN
of_IN
established_JJ
B_NN
cell_NN
lymphoma_NN
lines_NNS
is_VBZ
a_DT
novel_JJ
function_NN
of_IN
EBNA2_NN
which_WDT
has_VBZ
not_RB
been_VBN
detected_VBN
in_IN
the_DT
absence_NN
of_IN
an_DT
inducible_JJ
system_NN
._.

It_PRP
remains_VBZ
open_JJ
whether_IN
the_DT
growth_NN
retarding_NN
property_NN
of_IN
the_DT
EBNA2-oestrogen_JJ
receptor_NN
fusion_NN
protein_NN
in_IN
B_NN
cell_NN
lymphoma_NN
lines_NNS
is_VBZ
due_JJ
to_TO
unphysiologically_RB
high_JJ
expression_NN
of_IN
the_DT
chimeric_JJ
protein_NN
or_CC
to_TO
interference_NN
with_IN
a_DT
cellular_JJ
program_NN
driving_VBG
proliferation_NN
in_IN
these_DT
cell_NN
lines_NNS
._.

